UBS Initiates Coverage On Rapport Therapeutics with Buy Rating, Announces Price Target of $71

UBS analyst Joon Lee has initiated coverage on Rapport Therapeutics (NASDAQ: RAPP) with a Buy rating. The firm has set a price target of $71 for the company's stock.